An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis

TianMei Si,1 QingRong Tan,2 KeRang Zhang,3 Yang Wang,4 Qing Rui4 1Peking University Institute of Mental health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 2Fourth Military Medical University, First Hospital, Xi’an, 3Shanxi Medical University, First H...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Si TM, Tan QR, Zhang KR, Wang Y, Rui Q
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/109b418228ca44afa9ba3557d3367584
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:109b418228ca44afa9ba3557d3367584
record_format	dspace
spelling	oai:doaj.org-article:109b418228ca44afa9ba3557d33675842021-12-02T09:52:14ZAn open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis1178-2021https://doaj.org/article/109b418228ca44afa9ba3557d33675842015-01-01T00:00:00Zhttp://www.dovepress.com/an-open-label-flexible-dose-study-of-paliperidone-extended-release-in--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 TianMei Si,1 QingRong Tan,2 KeRang Zhang,3 Yang Wang,4 Qing Rui4 1Peking University Institute of Mental health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 2Fourth Military Medical University, First Hospital, Xi’an, 3Shanxi Medical University, First Hospital, Shanxi, 4Janssen Research and Development, Beijing, People’s Republic of China Background: Antipsychotic medications facilitate the improvement of psychotic symptoms in patients with first-episode psychosis. Paliperidone extended-release (pali-ER), an atypical antipsychotic, was assessed for efficacy and safety in Chinese patients with first-episode psychosis. Methods: In this 8-week, open-label, single-arm, multicenter study, patients with first-episode psychosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) and a Positive and Negative Syndrome Scale (PANSS) total score ≥70 were treated with flexible-dose pali-ER tablets (3–12 mg/day). The primary efficacy endpoint was the percentage of patients with an increase of ≥8 points in Personal and Social Performance (PSP) score from baseline to day 56 (8 weeks). Secondary endpoints included reduction in PANSS total score, improvement in Clinical Global Impression-Severity score, PSP score, Subjective Well-being under Neuroleptics Scale score, and relationship between duration of untreated psychosis and PANSS or PSP. Incidences of treatment-emergent adverse events were used to evaluate safety.Results: Overall, 283 of 294 patients (96%) achieved a ≥8-point increase in PSP (primary endpoint, analysis set). For the secondary efficacy endpoints, 284/306 patients (93%) had a ≥30% reduction in PANSS total score; 266/306 patients (87%) achieved a ≤3 Clinical Global Impression-Severity scale score, and 218/294 patients (74%) had a PSP score ≥71. The Subjective Well-being under Neuroleptics Scale score was improved from a baseline mean of 72.7 to 94.7 at endpoint. There was a negative correlation between duration of untreated psychosis and posttreatment PSP score and a positive correlation with posttreatment PANSS total score. The most common treatment-emergent adverse events were extrapyramidal symptoms (12%), and agitation, somnolence, and xerostomia (4% each).Conclusion: An 8-week, flexible-dose (3–12 mg/day) treatment with pali-ER resulted in significant improvements in psychotic symptoms and social functioning in Chinese patients with first-episode psychosis and was generally tolerable. Keywords: paliperidone, first-episode psychosis, Personal and Social Performance scoreSi TMTan QRZhang KRWang YRui QDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 87-95 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Si TM Tan QR Zhang KR Wang Y Rui Q An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
description	TianMei Si,1 QingRong Tan,2 KeRang Zhang,3 Yang Wang,4 Qing Rui4 1Peking University Institute of Mental health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, 2Fourth Military Medical University, First Hospital, Xi’an, 3Shanxi Medical University, First Hospital, Shanxi, 4Janssen Research and Development, Beijing, People’s Republic of China Background: Antipsychotic medications facilitate the improvement of psychotic symptoms in patients with first-episode psychosis. Paliperidone extended-release (pali-ER), an atypical antipsychotic, was assessed for efficacy and safety in Chinese patients with first-episode psychosis. Methods: In this 8-week, open-label, single-arm, multicenter study, patients with first-episode psychosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) and a Positive and Negative Syndrome Scale (PANSS) total score ≥70 were treated with flexible-dose pali-ER tablets (3–12 mg/day). The primary efficacy endpoint was the percentage of patients with an increase of ≥8 points in Personal and Social Performance (PSP) score from baseline to day 56 (8 weeks). Secondary endpoints included reduction in PANSS total score, improvement in Clinical Global Impression-Severity score, PSP score, Subjective Well-being under Neuroleptics Scale score, and relationship between duration of untreated psychosis and PANSS or PSP. Incidences of treatment-emergent adverse events were used to evaluate safety.Results: Overall, 283 of 294 patients (96%) achieved a ≥8-point increase in PSP (primary endpoint, analysis set). For the secondary efficacy endpoints, 284/306 patients (93%) had a ≥30% reduction in PANSS total score; 266/306 patients (87%) achieved a ≤3 Clinical Global Impression-Severity scale score, and 218/294 patients (74%) had a PSP score ≥71. The Subjective Well-being under Neuroleptics Scale score was improved from a baseline mean of 72.7 to 94.7 at endpoint. There was a negative correlation between duration of untreated psychosis and posttreatment PSP score and a positive correlation with posttreatment PANSS total score. The most common treatment-emergent adverse events were extrapyramidal symptoms (12%), and agitation, somnolence, and xerostomia (4% each).Conclusion: An 8-week, flexible-dose (3–12 mg/day) treatment with pali-ER resulted in significant improvements in psychotic symptoms and social functioning in Chinese patients with first-episode psychosis and was generally tolerable. Keywords: paliperidone, first-episode psychosis, Personal and Social Performance score
format	article
author	Si TM Tan QR Zhang KR Wang Y Rui Q
author_facet	Si TM Tan QR Zhang KR Wang Y Rui Q
author_sort	Si TM
title	An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
title_short	An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
title_full	An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
title_fullStr	An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
title_full_unstemmed	An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
title_sort	open-label, flexible-dose study of paliperidone extended-release in chinese patients with first-onset psychosis
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/109b418228ca44afa9ba3557d3367584
work_keys_str_mv	AT sitm anopenlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT tanqr anopenlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT zhangkr anopenlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT wangy anopenlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT ruiq anopenlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT sitm openlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT tanqr openlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT zhangkr openlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT wangy openlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis AT ruiq openlabelflexibledosestudyofpaliperidoneextendedreleaseinchinesepatientswithfirstonsetpsychosis
_version_	1718397988037984256

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis

Ejemplares similares